Titan Pharmaceuticals Inc (TTNP)

[Serenity3]

JAMA study Vivitrol vs oral Buprenorphine.. headline notes non-inferiority of Vivitrol .. but "More patients reported adverse events in the extended-release naltrexone group versus those in the buprenorphine-naloxone group (69.0% vs. 34.7%). A number of events in the extended-release naltrexone group, and to a lesser degree in the buprenorphine-naloxone group, were related to induced or experienced withdrawal symptoms, which the study investigators attribute largely to insufficient opioid detoxification. A change to the detoxification strategy was made during the first year of the study, which reduced the number of new adverse events related to induction of treatment"… so the study was changed to redefine detoxed folks as those who don't have cravings?.. don't know... haven't seen study methodology.. anyone out there combed through the details?

From <http://www.businesswire.com/news/home/20171018006067/en/New-Study-Comparing-Effectiveness-Extended-Release-Naltrexone-Buprenorphine-Naloxone>;